Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) Gross Margin (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Gross Margin for 15 consecutive years, with 92.88% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 207.0% year-over-year to 92.88%, compared with a TTM value of 92.25% through Sep 2025, up 209.0%, and an annual FY2024 reading of 90.61%, up 269.0% over the prior year.
  • Gross Margin was 92.88% for Q3 2025 at Sanara MedTech, roughly flat from 92.5% in the prior quarter.
  • Across five years, Gross Margin topped out at 92.88% in Q3 2025 and bottomed at 82.92% in Q3 2022.
  • Average Gross Margin over 5 years is 89.49%, with a median of 90.04% recorded in 2024.
  • The sharpest move saw Gross Margin soared 4132bps in 2021, then tumbled -820bps in 2022.
  • Year by year, Gross Margin stood at 88.87% in 2021, then decreased by -5bps to 84.53% in 2022, then rose by 6bps to 89.89% in 2023, then increased by 2bps to 91.45% in 2024, then grew by 2bps to 92.88% in 2025.
  • Business Quant data shows Gross Margin for SMTI at 92.88% in Q3 2025, 92.5% in Q2 2025, and 92.17% in Q1 2025.